scholarly journals Glioblastoma with Both Oligodendroglioma and Primitive Neuroectodermal Tumor-Like Components in a Case with 9-Year Survival

2018 ◽  
Vol 2018 ◽  
pp. 1-6 ◽  
Author(s):  
Ying-Tso Chen ◽  
Shu-Shong Hsu ◽  
Chi-Man Yip ◽  
Ping-Hong Lai ◽  
Huai-Pao Lee

Introduction. Glioblastoma multiforme (GBM), the most common primary malignant brain tumor in adults, is characterized by extensive heterogeneity in its clinicopathological presentation. A primary brain tumor with both astrocytic differentiation and neuronal immunophenotype features is rare. Here, we report a long-term survival patient who presented this rare form of GBM in the disease course. Presentation of Case. A 23-year-old woman, presenting with rapidly progressive headache and right-side weakness, was diagnosed with brain tumor over the left basal ganglion. She underwent the first craniectomy for tumor removal, and histopathology revealed classic GBM. Tumor recurrence occurred 8 years later. Another gross total resection was performed and pathology revealed GBM with the oligodendroglioma component (GBM-O). Due to disease progression, she received debulking surgery the following year. The third pathology revealed glioblastoma with primitive neuroectodermal tumor-like component (GBM-PNET). Discussion. GBM-PNETs are collision tumors with both neuronal and glial components. They are rare, and a few case reports have suggested that these tumors are associated with favorable outcomes but a higher risk of cerebrospinal fluid dissemination. Conclusion. We report a patient who developed the distinct pathologic variants of classic GBM, GBM-O, and GBM-PNET, throughout the disease course. Young age, aggressive surgical resection, and pathologic and genetic features may have contributed to the long-term survival of the patient.

2018 ◽  
Vol 33 (2) ◽  
pp. 263
Author(s):  
Lae Hyung Kang ◽  
Hyeong Jin Kim ◽  
Jin Ho Jang ◽  
Jun Hyun Kim ◽  
Kyoung Un Choi ◽  
...  

2019 ◽  
Vol 7 (3) ◽  
pp. 340-346 ◽  
Author(s):  
Jun Dai ◽  
Hong-Chao He ◽  
Xin Huang ◽  
Fu-Kang Sun ◽  
Yu Zhu ◽  
...  

2007 ◽  
Vol 24 (2) ◽  
pp. 69-74 ◽  
Author(s):  
Kenichiro Asano ◽  
Jyun Kikuchi ◽  
Akira Munakata ◽  
Hiroki Ohkuma ◽  
Osami Kubo

Author(s):  
Chao Wang ◽  
Min Shi ◽  
Lei Zhang ◽  
Jun Ji ◽  
Ruyan Xie ◽  
...  

Abstract Objective To investigate the molecular characteristics in tumor immune microenvironment that affect long-term survival of patients with pancreatic adenocarcinoma (PAAD). Methods The tumor related genetic features of a female PAAD patient (over 13-year survival) who suffered from multiple recurrences and metastases, and six operations over one decade were investigated deeply. Genomic features and immune microenvironment signatures of her primary lesion as well as six metastatic tumors at different time-points were characterized. Results High-frequency clonal neoantigenic mutations identified in these specimens revealed the significant associations between clonal neoantigens with her prognosis after each surgery. Meanwhile, the TCGA and ICGC databases were employed to analyse the function of KRAS G12V in pancreatic cancer. Conclusions The genomic analysis of clonal neoantigens combined with tumor immune microenvironment could promote the understandings of personalized prognostic evaluation and the stratification of resected PAAD individuals with better outcome.


Cancer ◽  
1979 ◽  
Vol 43 (2) ◽  
pp. 730-734 ◽  
Author(s):  
Merrill S. Kies ◽  
Dan W. Luedke ◽  
James F. Boyd ◽  
Miles J. McCue

2016 ◽  
Vol 18 (suppl_6) ◽  
pp. vi5-vi5
Author(s):  
Caroline Happold ◽  
Riccardo Soffietti ◽  
Christine Marosi ◽  
Jaap Reijneveld ◽  
Gabriele Schackert ◽  
...  

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. 2056-2056 ◽  
Author(s):  
Michael Weller ◽  
Guido Reifenberger ◽  
Emilie Le Rhun ◽  
Jennifer Leigh Clarke ◽  
Riccardo Soffietti ◽  
...  

2056 Background: Glioblastoma represents the most aggressive primary brain tumor in adults, and less than 5% of patients survive 5 years from diagnosis. Factors influencing this long-term survival are poorly understood. Methods: In cooperation with the European Organisation for Research and Treatment of Cancer (EORTC) in Brussels, Belgium, more than 20 clinical sites in the US, Europe and Australia have registered patients with centrally confirmed glioblastoma who survived ≥ 5 years, collecting clinical data including therapy and quality of life-related factors, as well as biospecimens allowing to analyse molecular and immunological parameters. Results: At the cut-off of December 31, 2018, 392 patients were registered, of which 232 had glioblastoma confirmed by central pathology review; 59 dropped out due to histology other than glioblastoma. Glioblastomas were isocitrate dehydrogenase (IDH)-wildtype in 70.7% and had a positive O6-methylguanine DNA methyltransferase (MGMT) promotor methylation status in 75.9%. Median age at diagnosis was 52 years (range: 21-77 years). There was enrichment for patients with gross total resection. Further analyses are ongoing. Conclusions: In a comprehensive effort, the consortium funded by the US Brain Tumor Funders’ Collaborative characterizes factors modulating long-term survival in glioblastoma in a unique large patient cohort. Clinical trial information: NCT 03770468.


Sign in / Sign up

Export Citation Format

Share Document